Author:
Li Na,Xu Tangpeng,Zhou Zhen,Li Ping,Jia Guohua,Li Xiangpan
Abstract
Penile squamous cell carcinoma (SCC) is a rare malignant tumor in males with a poor prognosis. Currently, the primary treatment is surgery. Recurrent cases have limited treatment options after failed radiotherapy and chemotherapy. The therapeutic effect of immunotherapy in penile SCCs has not been reported. Tislelizumab, a new PD1 inhibitor, has shown a satisfactory impact in treating head and neck SCC and lung SCC combined with chemotherapy. However, there is currently no report on its efficacy in penile SCC. Here, a 76-year-old man with multiple enlarged inguinal lymph nodes 11 months after radical surgery for penile SCC was administered immunotherapy (tislelizumab) combined with chemotherapy (albumin paclitaxel plus nedaplatin) for 2 cycles. Pelvic Magnetic resonance imaging (MRI) showed that the multiple lymph nodes in the groin area disappeared. To our knowledge, this is the first case report of immunotherapy combined with chemotherapy showing promising results in recurrent penile SCC. It provides a basis for developing a new treatment option combining immunotherapy and chemotherapy, whose efficacy needs to be further evaluated in penile SCC.
Funder
Natural Science Foundation of Hubei Province
Health and Family Planning Commission of Hubei Province
Reference47 articles.
1. EAU Guidelines on Penile Cancer: 2014 Update;Hakenberg;Eur Urol,2015
2. Invasive Penile Squamous Cell Carcinoma;Ogrich;Cutis,2018
3. Contemporary Management of Patients With Penile Cancer and Lymph Node Metastasis;Leone;Nat Rev Urol,2017
4. Inguinal Recurrence Following Therapeutic Lymphadenectomy for Node Positive Penile Carcinoma: Outcome and Implications for Management;Graafland;J Urol,2011
5. First-Line Therapy With Dacomitinib, an Orally Available Pan-HER Tyrosine Kinase Inhibitor, for Locally Advanced or Metastatic Penile Squamous Cell Carcinoma: Results of an Open-Label, Single-Arm, Single-Centre, Phase 2 Study;Necchi;BJU Int,2018
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献